Early onset sporadic colorectal cancer: Worrisome trends and oncogenic features

Digestive and Liver Disease

Volumn 50, Issue 6, 2018, Pages 521-532

  Cavestro, Giulia Martina ^a   Mannucci, Alessandro ^a   Zuppardo, Raffaella Alessia ^a   Di Leo, Milena ^b   Stoffel, Elena ^c   Tonon, Giovanni ^d  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^c UNIVERSITY OF MICHIGAN HOSPITALS   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

Comparison; Hypomethylation; Microsatellite and chromosomal instability; Molecular mechanism

Indexed keywords

ALCOHOL; TUMOR MARKER;

CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER PREVENTION; CANCER PROGNOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; DIETARY INTAKE; DNA METHYLATION; DRUG RESISTANCE; EARLY CANCER; GENETIC DISORDER; GERMLINE MUTATION; HUMAN; MICROSATELLITE INSTABILITY; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; SMOKING; CARCINOGENESIS; COLORECTAL TUMOR; GENETIC PREDISPOSITION; GENETICS; GENOMIC INSTABILITY; ONSET AGE; RISK FACTOR;

AGE OF ONSET; BIOMARKERS, TUMOR; CARCINOGENESIS; COLORECTAL NEOPLASMS; DNA METHYLATION; GENETIC PREDISPOSITION TO DISEASE; GENOMIC INSTABILITY; GERM-LINE MUTATION; HUMANS; RISK FACTORS;

EID: 85044567905     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2018.02.009     Document Type: Review

References (241)

1. Hubbard, J.M., Grothey, A., Adolescent and young adult colorectal cancer. J Natl Compr Cancer Netw 11 (2013), 1219–1225.
2. Stigliano, V., Early-onset colorectal cancer: a sporadic or inherited disease?. World J Gastroenterol, 20, 2014, 12420.
3. Ahnen, D.J., Wade, S.W., Jones, W.F., Sifri, R., Silveiras, J.M., Greenamyer, J., et al. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc 89 (2014), 216–224.
4. Chang, D.T., Pai, R.K., Rybicki, L.A., Dimaio, M.A., Limaye, M., Jayachandran, P., et al. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Mod Pathol 25 (2012), 1128–1139.
5. Goel, A., Nagasaka, T., Spiegel, J., Meyer, R., Lichliter, W.E., Boland, C.R., Low frequency of Lynch syndrome among young patients with non-familial colorectal cancer. Clin Gastroenterol Hepatol 8 (2010), 966–971.
6. Giraldez, M.D., Balaguer, F., Bujanda, L., Cuatrecasas, M., Munoz, J., Alonso-Espinaco, V., et al. MSH6 and MUTYH deficiency is a frequent event in early-onset colorectal cancer. Clin Cancer Res 16 (2010), 5402–5413.
7. Gryfe, R., Kim, H., Hsieh, E.T., Aronson, M.D., Holowaty, E.J., Bull, S.B., et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342 (2000), 69–77.
8. Stoffel, E.M., Koeppe, E., Everett, J., Ulintz, P., Kiel, M., Osborne, J., et al. Germline genetic features of young individuals with colorectal cancer. Gastroenterology, 2017, 10.1053/j.gastro.2017.11.004.
9. Bailey, C.E., Hu, C.-Y., You, Y.N., Bednarski, B.K., Rodriguez-Bigas, M.A., Skibber, J.M., et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975–2010. JAMA Surg 150 (2015), 17–22.
10. Gaudet, F., Hodgson, J.G., Eden, A., Jackson-Grusby, L., Dausman, J., Gray, J.W., et al. Induction of tumors in mice by genomic hypomethylation. Science 300 (2003), 489–492.
11. Bleyer, A., Barr, R., Hayes-Lattin, B., Thomas, D., Ellis, C., Anderson, B., The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer 8 (2008), 288–298.
12. Davis, D.M., Marcet, J.E., Frattini, J.C., Prather, A.D., Mateka, J.J.L., Nfonsam, V.N., Is it time to lower the recommended screening age for colorectal cancer?. J Am Coll Surg 213 (2011), 352–361.
13. O'Connell, J.B., Maggard, M.A., Livingston, E.H., Yo, C.K., Colorectal cancer in the young. Am J Surg 187 (2004), 343–348.
14. Dozois, E.J., Boardman, L.A., Suwanthanma, W., Limburg, P.J., Cima, R.R., Bakken, J.L., et al. Young-onset colorectal cancer in patients with no known genetic predisposition. Medicine 87 (2008), 259–263.
15. Liang, J.T., Huang, K.C., Cheng, A.L., Jeng, Y.M., Wu, M.S., Wang, S.M., Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age. Br J Surg 90 (2003), 205–214.
16. McMillan, D.C., McArdle, C.S., The impact of young age on cancer-specific and non-cancer-related survival after surgery for colorectal cancer: 10-year follow-up. Br J Cancer 101 (2009), 557–560.
17. Enblad, G., Enblad, P., Adami, H.O., Glimelius, B., Krusemo, U., Påhlman, L., Relationship between age and survival in cancer of the colon and rectum with special reference to patients less than 40 years of age. Br J Surg 77 (1990), 611–616.
18. Siegel, R.L., Miller, K.D., Fedewa, S.A., Ahnen, D.J., Meester, R.G.S., Barzi, A., et al. Colorectal cancer statistics, 2017. CA Cancer J Clin 67 (2017), 177–193.
19. Kam, M.H., Eu, K.W., Barben, C.P., Seow-Choen, F., Colorectal cancer in the young: a 12-year review of patients 30 years or less. Colorectal Dis 6 (2004), 191–194.
20. Rodriguez-Bigas, M.A., Mahoney, M.C., Weber, T.K., Petrelli, N.J., Colorectal cancer in patients aged 30 years or younger. Surg Oncol 5 (1996), 189–194.
21. You, Y.N., Nancy You, Y., Young-onset colorectal cancer: is it time to pay attention?. Arch Intern Med, 172, 2012, 287.
22. Siegel, R.L., Jemal, A., Ward, E.M., Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev 18 (2009), 1695–1698.
23. Holowatyj, A.N., Ruterbusch, J.J., Rozek, L.S., Cote, M.L., Stoffel, E.M., Racial/ethnic disparities in survival among patients with young-onset colorectal cancer. J Clin Oncol 34 (2016), 2148–2156.
24. Eusebi, L.H., Ceccarelli, C., Artesiani, M.L., Montanaro, L., Derenzini, M., Dall'Olio, F., et al. 08.16: early onset colorectal cancer vs sporadic colorectal cancer: a clinicopathological and molecular comparison. Dig Liver Dis 49 (2017), e185–e186.
25. Theuer, C.P., Wagner, J.L., Taylor, T.H., Brewster, W.R., Tran, D., McLaren, C.E., et al. Racial and ethnic colorectal cancer patterns affect the cost-effectiveness of colorectal cancer screening in the United States. Gastroenterology 120 (2001), 848–856.
26. Amini, A.Q., Samo, K.A., Memon, A.S., Colorectal cancer in younger population: our experience. J Pak Med Assoc 63 (2013), 1275–1277.
27. Gupta, S., Bhattacharya, D., Acharya, A.N., Majumdar, S., Ranjan, P., Das, S., Colorectal carcinoma in young adults: a retrospective study on Indian patients: 2000-2008. Colorectal Dis 12 (2010), e182–e189.
28. Saluja, S.S., Manipadam, J.M., Mishra, P.K., Sachdeva, S., Solanki, N., Shah, H., Young onset colorectal cancer: How does it differ from its older counterpart?. Indian J Cancer 51 (2014), 565–569.
29. Soliman, A.S., Bondy, M.L., Levin, B., Hamza, M.R., Ismail, K., Ismail, S., et al. Colorectal cancer in Egyptian patients under 40 years of age. Int J Cancer 71 (1997), 26–30.
30. Singh, Y., Vaidya, P., Hemandas, A.K., Singh, K.P., Khakurel, M., Colorectal carcinoma in Nepalese young adults: presentation and outcome. Gan To Kagaku Ryoho 29:Suppl 1 (2002), 223–229.
31. Isbister, W.H., Colorectal cancer below age 40 in the Kingdom of Saudi Arabia. Aust N Z J Surg 62 (1992), 468–472.
32. De Silva, M., Fernando, M.S., Fernando, D., Comparison of some clinical and histological features of colorectal carcinoma occurring in patients below and above 40 years. Ceylon Med J, 45, 2014, 10.4038/cmj.v45i4.6722.
33. Yilmazlar, T., Zorluoğlu, A., Ozgüç, H., Korun, N., Duman, H., Kaya, E., et al. Colorectal cancer in young adults. Tumori 81 (1995), 230–233.
34. Yeo, S.A., Chew, M.H., Koh, P.K., Tang, C.L., Young colorectal carcinoma patients do not have a poorer prognosis: a comparative review of 2,426 cases. Tech Coloproctol 17 (2013), 653–661.
35. Han-Shiang, C., Curative resection of colorectal adenocarcinoma: multivariate analysis of 5-year follow-up. World J Surg 23 (1999), 1301–1306.
36. Bacon, H.E., Sealy, W.B., Malignancy of the anus, rectum and sigmoid colon in the young. Am J Surg 45 (1939), 339–347.
37. Young, J.P., Win, A.K., Rosty, C., Flight, I., Roder, D., Young, G.P., et al. Rising incidence of early-onset colorectal cancer in Australia over two decades: report and review. J Gastroenterol Hepatol 30 (2015), 6–13.
38. Steliarova-Foucher, E., Stiller, C., Kaatsch, P., Berrino, F., Coebergh, J.-W., Lacour, B., et al. Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970 (the ACCISproject): an epidemiological study. Lancet 364 (2004), 2097–2105.
39. Merrill, R.M., Anderson, A.E., Risk-adjusted colon and rectal cancer incidence rates in the United States. Dis Colon Rectum 54 (2011), 1301–1306.
40. O'Connell, J.B., Maggard, M.A., Liu, J.H., Etzioni, D.A., Livingston, E.H., Ko, C.Y., Rates of colon and rectal cancers are increasing in young adults. Am Surg 69 (2003), 866–872.
41. Ponz de Leon, M., Roncucci, L., The cause of colorectal cancer. Dig Liver Dis 32 (2000), 426–439.
42. Centers for Disease Control and Prevention (CDC), Trends in leisure-time physical inactivity by age, sex, and race/ethnicity—United States, 1994-2004. MMWR Morb Mortal Wkly Rep 54 (2004), 991–994.
43. Flegal, K.M., Carroll, M.D., Ogden, C.L., Curtin, L.R., Prevalence and trends in obesity among US adults, 1999-2008. JAMA 303 (2010), 235–241.
44. Wolin, K.Y., Yan, Y., Colditz, G.A., Lee, I.-M., Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer 100 (2009), 611–616.
45. Ferrari, P., Jenab, M., Norat, T., Moskal, A., Slimani, N., Olsen, A., et al. Lifetime and baseline alcohol intake and risk of colon and rectal cancers in the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer 121 (2007), 2065–2072.
46. Botteri, E., Iodice, S., Bagnardi, V., Raimondi, S., Lowenfels, A.B., Maisonneuve, P., Smoking and colorectal cancer: a meta-analysis. JAMA 300 (2008), 2765–2778.
47. Caetano, R., Clark, C.L., Trends in alcohol consumption patterns among whites, blacks and Hispanics: 1984 and 1995. J Stud Alcohol 59 (1998), 659–668.
48. Rehm J, Shield K, Rehm M, Gmel G, Frick U. Alcohol Consumption, Alcohol Dependence and Attributable Burden of Disease in Europe: Potential Gains From Effective Interventions for Alcohol Dependence. PsycEXTRA Dataset n.d. doi: 10.1037/e506502014-001.
49. Gual, A., Colom, J., Why has alcohol consumption declined in countries of southern Europe?. Addiction 92:Suppl 1 (1997), S21–S31.
50. [No title] n.d. https://www.istat.it/it/files/2017/04/Consumo_alcol_in_Italia_2016.pdf?title=Consumo+di+alcol++-+12%2Fapr%2F2017+-+Testo+integrale+e+nota+metodologica.pdf [Accessed 16 September 2017].
51. Larsson, S.C., Wolk, A., Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int J Cancer 119 (2006), 2657–2664.
52. Cho, E., Smith-Warner, S.A., Spiegelman, D., Beeson, W.L., van den Brandt, P.A., Colditz, G.A., et al. Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst 96 (2004), 1015–1022.
53. Guthrie, J.F., Lin, B.-H., Frazao, E., Role of food prepared away from home in the American diet, 1977-78 versus 1994-96: changes and consequences. J Nutr Educ Behav 34 (2002), 140–150.
54. Pereira, M.A., Kartashov, A.I., Ebbeling, C.B., Van Horn, L., Slattery, M.L., Jacobs, D.R. Jr, et al. Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. Lancet 365 (2005), 36–42.
55. Bowman, S.A., Gortmaker, S.L., Ebbeling, C.B., Pereira, M.A., Ludwig, D.S., Effects of fast-food consumption on energy intake and diet quality among children in a national household survey. Pediatrics 113 (2003), 112–118.
56. Watson, R., Liu, T.-C., Ruzinova, M.B., High frequency of KRAS mutation in early onset colorectal adenocarcinoma: implications for pathogenesis. Hum Pathol 56 (2016), 163–170.
57. Yantiss, R.K., Goodarzi, M., Zhou, X.K., Rennert, H., Pirog, E.C., Banner, B.F., et al. Clinical, pathologic, and molecular features of early-onset colorectal carcinoma. Am J Surg Pathol 33 (2009), 572–582.
58. Ricciardiello, L., Chang, D.K., Laghi, L., Goel, A., Chang, C.L., Boland, C.R., Mad-1 is the exclusive JC virus strain present in the human colon, and its transcriptional control region has a deleted 98-base-pair sequence in colon cancer tissues. J Virol 75 (2001), 1996–2001.
59. Laghi, L., Randolph, A.E., Chauhan, D.P., Marra, G., Major, E.O., Neel, J.V., et al. JC virus DNA is present in the mucosa of the human colon and in colorectal cancers. Proc Natl Acad Sci U S A 96 (1999), 7484–7489.
60. Enam, S., Del Valle, L., Lara, C., Gan, D.-D., Ortiz-Hidalgo, C., Palazzo, J.P., et al. Association of human polyomavirus JCV with colon cancer: evidence for interaction of viral T-antigen and beta-catenin. Cancer Res 62 (2002), 7093–7101.
61. Coelho, T.R., Gaspar, R., Figueiredo, P., Mendonça, C., Lazo, P.A., Almeida, L., Human JC polyomavirus in normal colorectal mucosa, hyperplastic polyps, sporadic adenomas, and adenocarcinomas in Portugal. J Med Virol 85 (2013), 2119–2127.
62. Yuhara, H., Steinmaus, C., Cohen, S.E., Corley, D.A., Tei, Y., Buffler, P.A., Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer?. Am J Gastroenterol 106 (2011), 1911–1921 quiz 1922.
63. Larsson, S.C., Orsini, N., Wolk, A., Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97 (2005), 1679–1687.
64. Pan, S.Y., DesMeules, M., Energy intake, physical activity, energy balance, and cancer: epidemiologic evidence. Methods Mol Biol, 2009, 191–215.
65. Ekbom, A., Helmick, C., Zack, M., Adami, H.O., Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323 (1990), 1228–1233.
66. Terzić, J., Grivennikov, S., Karin, E., Karin, M., nflammation and colon cancer. Gastroenterology, 138, 2010 2101–2114.e5.
67. Schetter, A.J., Nguyen, G.H., Bowman, E.D., Mathé, E.A., Yuen, S.T., Hawkes, J.E., et al. Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res 15 (2009), 5878–5887.
68. Couturier-Maillard, A., Secher, T., Rehman, A., Normand, S., De Arcangelis, A., Haesler, R., et al. NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer. J Clin Invest 123 (2013), 700–711.
69. Elinav, E., Strowig, T., Kau, A.L., Henao-Mejia, J., Thaiss, C.A., Booth, C.J., et al. NLRP6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145 (2011), 745–757.
70. Sobhani, I., Tap, J., Roudot-Thoraval, F., Roperch, J.P., Letulle, S., Langella, P., et al. Microbial dysbiosis in colorectal cancer (CRC) patients. PLoS One, 6, 2011, e16393.
71. Rakoff-Nahoum, S., Hao, L., Medzhitov, R., Role of toll-like receptors in spontaneous commensal-dependent colitis. Immunity 25 (2006), 319–329.
72. Uronis, J.M., Mühlbauer, M., Herfarth, H.H., Rubinas, T.C., Jones, G.S., Jobin, C., Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One, 4, 2009, e6026.
73. Kado, S., Uchida, K., Funabashi, H., Iwata, S., Nagata, Y., Ando, M., et al. Intestinal microflora are necessary for development of spontaneous adenocarcinoma of the large intestine in T-cell receptor beta chain and p53 double-knockout mice. Cancer Res 61 (2001), 2395–2398.
74. Rakoff-Nahoum, S., Medzhitov, R., Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 317 (2007), 124–127.
75. Arthur, J.C., Jobin, C., The struggle within: microbial influences on colorectal cancer. Inflamm Bowel Dis 17 (2011), 396–409.
76. Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S., Medzhitov, R., Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118 (2004), 229–241.
77. Tanaka, T., Kohno, H., Suzuki, R., Yamada, Y., Sugie, S., Mori, H., A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 94 (2003), 965–973.
78. Antelo, M., Balaguer, F., Shia, J., Shen, Y., Hur, K., Moreira, L., et al. A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. PLoS One, 7, 2012, e45357.
79. Turkiewicz, D., Miller, B., Schache, D., Cohen, J., Theile, D., Young patients with colorectal cancer: how do they fare?. ANZ J Surg 71 (2001), 707–710.
80. Stigliano, V., Sanchez-Mete, L., Martayan, A., Diodoro, M., Casini, B., Sperduti, I., et al. Early-onset colorectal cancer patients without family history are “at very low risk” for lynch syndrome. J Exp Clin Cancer Res, 33, 2014, 1.
81. Khan, S.A., Morris, M., Idrees, K., Gimbel, M.I., Rosenberg, S., Zeng, Z., et al. Colorectal cancer in the very young: a comparative study of tumor markers, pathology and survival in early onset and adult onset patients. J Pediatr Surg 51 (2016), 1812–1817.
82. Mork, M.E., Nancy You, Y., Ying, J., Bannon, S.A., Lynch, P.M., Rodriguez-Bigas, M.A., et al. High prevalence of hereditary cancer syndromes in adolescents and young adults with colorectal cancer. J Clin Oncol 33 (2015), 3544–3549.
83. Buttin, B.M., Powell, M.A., Mutch, D.G., Babb, S.A., Huettner, P.C., Edmonston, T.B., et al. Penetrance and expressivity of MSH6 germline mutations in seven kindreds not ascertained by family history. Am J Hum Genet 74 (2004), 1262–1269.
84. Pearlman, R., Frankel, W.L., Swanson, B., Zhao, W., Yilmaz, A., Miller, K., et al. Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer. JAMA Oncol 3 (2017), 464–471.
85. Hampel, H., Bennett, R.L., Buchanan, A., Pearlman, R., Wiesner, G.L., Guideline Development Group, American College of Medical Genetics and Genomics Professional Practice and Guidelines Committee and National Society of Genetic Counselors Practice Guidelines Committee, A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment. Genet Med 17 (2015), 70–87.
86. Green, R.C., Berg, J.S., Grody, W.W., Kalia, S.S., Korf, B.R., Martin, C.L., et al. CORRIGENDUM: ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med, 19, 2017, 606.
87. Green, R.C., Berg, J.S., Grody, W.W., Kalia, S.S., Korf, B.R., Martin, C.L., et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 15 (2013), 565–574.
88. Robson, M.E., Bradbury, A.R., Arun, B., Domchek, S.M., Ford, J.M., Hampel, H.L., et al. American Society of Clinical oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 33 (2015), 3660–3667.
89. Kurian, A.W., Hare, E.E., Mills, M.A., Kingham, K.E., McPherson, L., Whittemore, A.S., et al. Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol 32 (2014), 2001–2009.
90. Palles, C., Cazier, J.-B., Howarth, K.M., Domingo, E., Jones, A.M., Broderick, P., et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet 45 (2013), 136–144.
91. Albertson, T.M., Ogawa, M., Bugni, J.M., Hays, L.E., Chen, Y., Wang, Y., et al. DNA polymerase epsilon and delta proofreading suppress discrete mutator and cancer phenotypes in mice. Proc Natl Acad Sci U S A 106 (2009), 17101–17104.
92. Losi, L., Di Gregorio, C., Pedroni, M., Ponti, G., Roncucci, L., Scarselli, A., et al. Molecular genetic alterations and clinical features in early-onset colorectal carcinomas and their role for the recognition of hereditary cancer syndromes. Am J Gastroenterol 100 (2005), 2280–2287.
93. Website n.d. National Comprehensive Care Network: Colon Cancer. http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. [Accessed 14 October 2017].
94. Frampton, G.M., Fichtenholtz, A., Otto, G.A., Wang, K., Downing, S.R., He, J., et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 31 (2013), 1023–1031.
95. Stoffel, E.M., Colorectal cancer in young individuals: opportunities for prevention. J Clin Oncol 33 (2015), 3525–3527.
96. Soares, B.L., Brant, A.C., Gomes, R., Pastor, T., Schneider, N.B., Ribeiro-Dos-Santos Â, et al. Screening for germline mutations in mismatch repair genes in patients with Lynch syndrome by next generation sequencing. Fam Cancer, 2017, 10.1007/s10689-017-0043-5.
97. Kuiper, R.P., Hoogerbrugge, N., NTHL1 defines novel cancer syndrome. Oncotarget 6:33 (2015), 34069–34070, 10.18632/oncotarget.5864.
98. Rivera, B., Castellsagué, E., Bah, I., van Kempen, L.C., Foulkes, W.D., Biallelic NTHL1 mutations in a woman with multiple primary tumors. N Engl J Med 373 (2015), 1985–1986.
99. Weren, R.D.A., Ligtenberg, M.J.L., Marleen Kets, C., de Voer, R.M., Verwiel, E.T.P., Spruijt, L., et al. A germline homozygous mutation in the base-excision repair gene NTHL1 causes adenomatous polyposis and colorectal cancer. Nat Genet 47 (2015), 668–671.
100. Adam, R., Spier, I., Zhao, B., Kloth, M., Marquez, J., Hinrichsen, I., et al. Exome sequencing identifies biallelic MSH3 germline mutations as a recessive subtype of colorectal adenomatous polyposis. Am J Hum Genet 99 (2016), 337–351.
101. Cicek, M.S., Cunningham, J.M., Fridley, B.L., Serie, D.J., Bamlet, W.R., Diergaarde, B., et al. Colorectal cancer linkage on chromosomes 4q21, 8q13, 12q24, and 15q22. PLoS One, 7, 2012, e38175.
102. Baert-Desurmont, S., Charbonnier, F., Houivet, E., Ippolito, L., Mauillon, J., Bougeard, M., et al. Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer risk. Eur J Hum Genet 24 (2016), 99–105.
103. Vogelstein, B., Kinzler, K.W., The path to cancer — three strikes and you're out. N Engl J Med 373 (2015), 1895–1898.
104. Vogelstein, B., Papadopoulos, N., Velculescu, V.E., Zhou, S., Diaz, L.A. Jr, Kinzler, K.W., Cancer genome landscapes. Science 339 (2013), 1546–1558.
105. Simanshu, D.K., Nissley, D.V., McCormick, F., RAS proteins and their regulators in human disease. Cell 170 (2017), 17–33.
106. Kastenhuber, E.R., Lowe, S.W., Putting p53 in context. Cell 170 (2017), 1062–1078.
107. Hanahan, D., Weinberg, R.A., The hallmarks of cancer. Cell 100 (2000), 57–70.
108. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
109. Lengauer, C., Kinzler, K.W., Vogelstein, B., Genetic instability in colorectal cancers. Nature 386 (1997), 623–627.
110. Pino, M.S., Chung, D.C., The chromosomal instability pathway in colon cancer. Gastroenterology 138 (2010), 2059–2072.
111. Jass, J.R., Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 50 (2007), 113–130.
112. Mundade, R., Imperiale, T.F., Prabhu, L., Loehrer, P.J., Lu, T., Genetic pathways, prevention, and treatment of sporadic colorectal cancer. Oncoscience 1 (2014), 400–406.
113. Ballester, V., Rashtak, S., Boardman, L., Clinical and molecular features of young-onset colorectal cancer. World J Gastroenterol 22 (2016), 1736–1744.
114. Boardman, L.A., Johnson, R.A., Petersen, G.M., Oberg, A.L., Kabat, B.F., Slusser, J.P., et al. Higher frequency of diploidy in young-onset microsatellite-stable colorectal cancer. Clin Cancer Res 13 (2007), 2323–2328.
115. Kirzin, S., Marisa, L., Guimbaud, R., De Reynies, A., Legrain, M., Laurent-Puig, P., et al. Sporadic early-onset colorectal cancer is a specific sub-type of cancer: a morphological, molecular and genetics study. PLoS One, 9, 2014, e103159.
116. Ogino, S., Nosho, K., Kirkner, G.J., Kawasaki, T., Meyerhardt, J.A., Loda, M., et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 58 (2008), 90–96.
117. Yachida, S., Mudali, S., Martin, S.A., Montgomery, E.A., Iacobuzio-Donahue, C.A., Beta-catenin nuclear labeling is a common feature of sessile serrated adenomas and correlates with early neoplastic progression after BRAF activation. Am J Surg Pathol 33 (2009), 1823–1832.
118. Wu, J.M., Montgomery, E.A., Iacobuzio-Donahue, C.A., Frequent beta-catenin nuclear labeling in sessile serrated polyps of the colorectum with neoplastic potential. Am J Clin Pathol 129 (2008), 416–423.
119. Raut, C.P., Pawlik, T.M., Rodriguez-Bigas, M.A., Clinicopathologic features in colorectal cancer patients with microsatellite instability. Mutat Res Fundam Mol Mech Mutagen 568 (2004), 275–282.
120. Bardhan, K., Liu, K., Epigenetics and colorectal cancer pathogenesis. Cancers 5 (2013), 676–713.
121. Arriba, M., García, J.L., Inglada-Pérez, L., Rueda, D., Osorio, I., Rodríguez, Y., et al. DNA copy number profiling reveals different patterns of chromosomal instability within colorectal cancer according to the age of onset. Mol Carcinog 55 (2015), 705–716.
122. Berg, M., Agesen, T.H., Thiis-Evensen, E., INFAC-study group, Merok, M.A., Teixeira, M.R., et al. Distinct high resolution genome profiles of early onset and late onset colorectal cancer integrated with gene expression data identify candidate susceptibility loci. Mol Cancer, 9, 2010, 100.
123. Tan, C., Du, X., KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol 18 (2012), 5171–5180.
124. Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., O'Callaghan, C.J., Tu, D., Tebbutt, N.C., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359 (2008), 1757–1765.
125. Laurent-Puig, P., Cayre, A., Manceau, G., Buc, E., Bachet, J.-B., Lecomte, T., et al. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. J Clin Oncol 27 (2009), 5924–5930.
126. Siddiqui, A.D., Piperdi, B., KRAS mutation in colon cancer: a marker of resistance to EGFR-I therapy. Ann Surg Oncol 17 (2010), 1168–1176.
127. Cancer Genome Atlas Network, Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (2012), 330–337.
128. Phipps, A.I., Limburg, P.J., Baron, J.A., Burnett-Hartman, A.N., Weisenberger, D.J., Laird, P.W., et al. Association between molecular subtypes of colorectal cancer and patient survival. Gastroenterology, 148, 2015 77–87.e2.
129. Alsop, K., Mead, L., Smith, L.D., Royce, S.G., Tesoriero, A.A., Young, J.P., et al. Low somatic K-ras mutation frequency in colorectal cancer diagnosed under the age of 45 years. Eur J Cancer 42 (2006), 1357–1361.
130. Samowitz, W.S., Albertsen, H., Herrick, J., Levin, T.R., Sweeney, C., Murtaugh, M.A., et al. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129 (2005), 837–845.
131. Nosho, K., Irahara, N., Shima, K., Kure, S., Kirkner, G.J., Schernhammer, E.S., et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One, 3, 2008, e3698.
132. English, D.R., Young, J.P., Simpson, J.A., Jenkins, M.A., Southey, M.C., Walsh, M.D., et al. Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev 17 (2008), 1774–1780.
133. Laurent-Puig, P., Manceau, G., Zucman-Rossi, J., Blons, H., Dual blockade of epidermal growth factor receptor-induced pathways: a new avenue to treat metastatic colorectal cancer. J Clin Oncol 30 (2012), 1550–1552.
134. Beroukhim, R., Mermel, C.H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., et al. The landscape of somatic copy-number alteration across human cancers. Nature 463 (2010), 899–905.
135. Ried, T., Heselmeyer-Haddad, K., Blegen, H., Schröck, E., Auer, G., Genomic changes defining the genesis, progression, and malignancy potential in solid human tumors: a phenotype/genotype correlation. Genes Chromosomes Cancer 25 (1999), 195–204.
136. Leslie, A., Carey, F.A., Pratt, N.R., Steele, R.J.C., The colorectal adenoma-carcinoma sequence. Br J Surg 89 (2002), 845–860.
137. Khosraviani, K., Colorectal adenoma-carcinoma sequence. Gut, 39, 1996, 342.
138. Fernandez-Rozadilla, C., Brea-Fernández, A., Bessa, X., Alvarez-Urturi, C., Abulí, A., Clofent, J., et al. BMPR1A mutations in early-onset colorectal cancer with mismatch repair proficiency. Clin Genet 84 (2013), 94–96.
139. Freyaldenhoven, B.S., Fried, C., Wielckens, K., FOXD4a and FOXD4b, two new winged helix transcription factors, are expressed in human leukemia cell lines. Gene 294 (2002), 131–140.
140. Kim, Y.-J., Jung, Y.-D., Kim, T.-O., Kim, H.-S., Alu-related transcript of TJP2 gene as a marker for colorectal cancer. Gene 524 (2013), 268–274.
141. Yang, W.-L., Perillo, W., Liou, D., Marambaud, P., Wang, P., AMPK inhibitor compound C suppresses cell proliferation by induction of apoptosis and autophagy in human colorectal cancer cells. J Surg Oncol 106 (2012), 680–688.
142. Chan, T.L., Curtis, L.C., Leung, S.Y., Farrington, S.M., Ho, J.W., Chan, A.S., et al. Early-onset colorectal cancer with stable microsatellite DNA and near-diploid chromosomes. Oncogene 20 (2001), 4871–4876.
143. Banerjea, A., Hands, R.E., Powar, M.P., Bustin, S.A., Dorudi, S., Microsatellite and chromosomal stable colorectal cancers demonstrate poor immunogenicity and early disease recurrence. Colorectal Dis 11 (2009), 601–608.
144. Boardman, L.A., Johnson, R.A., Viker, K.B., Hafner, K.A., Jenkins, R.B., Riegert-Johnson, D.L., et al. Correlation of chromosomal instability, telomere length and telomere maintenance in microsatellite stable rectal cancer: a molecular subclass of rectal cancer. PLoS One, 8, 2013, e80015.
145. Hawkins, N.J., Tomlinson, I., Meagher, A., Ward, R.L., Microsatellite-stable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer. Br J Cancer 84 (2001), 232–236.
146. Suzuki, K., Suzuki, I., Leodolter, A., Alonso, S., Horiuchi, S., Yamashita, K., et al. Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell 9 (2006), 199–207.
147. Goelz, S.E., Vogelstein, B., Hamilton, S.R., Feinberg, A.P., Hypomethylation of DNA from benign and malignant human colon neoplasms. Science 228 (1985), 187–190.
148. Holm, T.M., Jackson-Grusby, L., Brambrink, T., Yamada, Y., Rideout, W.M. 3rd, Jaenisch, R., Global loss of imprinting leads to widespread tumorigenesis in adult mice. Cancer Cell 8 (2005), 275–285.
149. Chalitchagorn, K., Shuangshoti, S., Hourpai, N., Kongruttanachok, N., Tangkijvanich, P., Thong-ngam, D., et al. Distinctive pattern of LINE-1 methylation level in normal tissues and the association with carcinogenesis. Oncogene 23 (2004), 8841–8846.
150. Matsuzaki, K., Deng, G., Tanaka, H., Kakar, S., Miura, S., Kim, Y.S., The relationship between global methylation level, loss of heterozygosity, and microsatellite instability in sporadic colorectal cancer. Clin Cancer Res 11 (2005), 8564–8569.
151. Yamada, Y., Jackson-Grusby, L., Linhart, H., Meissner, A., Eden, A., Lin, H., et al. Opposing effects of DNA hypomethylation on intestinal and liver carcinogenesis. Proc Natl Acad Sci U S A 102 (2005), 13580–13585.
152. Sheaffer, K.L., Elliott, E.N., Kaestner, K.H., DNA hypomethylation contributes to genomic instability and intestinal cancer initiation. Cancer Prev Res 9 (2016), 534–546.
153. Berman, B.P., Weisenberger, D.J., Aman, J.F., Hinoue, T., Ramjan, Z., Liu, Y., et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina?associated domains. Nat Genet 44 (2011), 40–46.
154. Luo, Y., Wong, C.-J., Kaz, A.M., Dzieciatkowski, S., Carter, K.T., Morris, S.M., et al. Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer. Gastroenterology, 147, 2014 418–29.e8.
155. Tahiliani, M., Koh, K.P., Shen, Y., Pastor, W.A., Bandukwala, H., Brudno, Y., et al. Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1. Science 324 (2009), 930–935.
156. Cortellino, S., Xu, J., Sannai, M., Moore, R., Caretti, E., Cigliano, A., et al. Thymine DNA glycosylase is essential for active DNA demethylation by linked deamination-base excision repair. Cell 146 (2011), 67–79.
157. Silver, A., Sengupta, N., Propper, D., Wilson, P., Hagemann, T., Patel, A., et al. A distinct DNA methylation profile associated with microsatellite and chromosomal stable sporadic colorectal cancers. Int J Cancer 130 (2011), 1082–1092.
158. Ogino, S., Kawasaki, T., Nosho, K., Ohnishi, M., Suemoto, Y., Kirkner, G.J., et al. LINE-1 hypomethylation is inversely associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer. Int J Cancer 122 (2008), 2767–2773.
159. Estécio, M.R.H., Gharibyan, V., Shen, L., Ibrahim, A.E.K., Doshi, K., He, R., et al. LINE-1 hypomethylation in cancer is highly variable and inversely correlated with microsatellite instability. PLoS One, 2, 2007, e399.
160. Baba, Y., Huttenhower, C., Nosho, K., Tanaka, N., Shima, K., Hazra, A., et al. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol Cancer, 9, 2010, 125.
161. Ogino, S., Nishihara, R., Lochhead, P., Imamura, Y., Kuchiba, A., Morikawa, T., et al. Prospective study of family history and colorectal cancer risk by tumor LINE-1 methylation level. J Natl Cancer Inst 105 (2013), 130–140.
162. Mima, K., Nowak, J.A., Qian, Z.R., Cao, Y., Song, M., Masugi, Y., et al. Tumor LINE-1 methylation level and colorectal cancer location in relation to patient survival. Oncotarget 7 (2016), 55098–55109.
163. Cai, G., Xu, Y., Lu, H., Shi, Y., Lian, P., Peng, J., et al. Clinicopathologic and molecular features of sporadic microsatellite- and chromosomal-stable colorectal cancers. Int J Colorectal Dis 23 (2008), 365–373.
164. Silla, I.O., Rueda, D., Rodríguez, Y., García, J.L., de la Cruz Vigo, F., Perea, J., Early-onset colorectal cancer: a separate subset of colorectal cancer. World J Gastroenterol 20 (2014), 17288–17296.
165. Rodriguez, J., Frigola, J., Vendrell, E., Risques, R.-A., Fraga, M.F., Morales, C., et al. Chromosomal instability correlates with genome-wide DNA demethylation in human primary colorectal cancers. Cancer Res 66 (2006), 8462–9468.
166. Fairley, T.L., Cardinez, C.J., Martin, J., Alley, L., Friedman, C., Edwards, B., et al. Colorectal cancer in U. S. adults younger than 50 years of age, 1998–2001. Cancer 107 (2006), 1153–1161.
167. Domergue, J., Ismail, M., Astre, C., Saint-Aubert, B., Joyeux, H., Solassol, C., et al. Colorectal carcinoma in patients younger than 40 years of age. Montpellier Cancer Institute experience with 78 patients. Cancer 61 (1988), 835–840.
168. Griffin, P.M., Liff, J.M., Greenberg, R.S., Clark, W.S., Adenocarcinomas of the colon and rectum in persons under 40 years old. Gastroenterology 100 (1991), 1033–1040.
169. Giráldez, M.D., López-Dóriga, A., Bujanda, L., Abulí, A., Bessa, X., Fernández-Rozadilla, C., et al. Susceptibility genetic variants associated with early-onset colorectal cancer. Carcinogenesis 33 (2012), 613–619.
170. Perea, J., Rodríguez, Y., Rueda, D., Marín, J.C., Díaz-Tasende, J., Álvaro, E., et al. Early-onset colorectal cancer is an easy and effective tool to identify retrospectively Lynch syndrome. Ann Surg Oncol 18 (2011), 3285–3291.
171. Kneuertz, P.J., Chang, G.J., Hu, C.-Y., Rodriguez-Bigas, M.A., Eng, C., Vilar, E., et al. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA Surg 150 (2015), 402–409.
172. Meyer, J.E., Narang, T., Schnoll-Sussman, F.H., Pochapin, M.B., Christos, P.J., Sherr, D.L., Increasing incidence of rectal cancer in patients aged younger than 40 years. Cancer 116 (2010), 4354–4359.
173. Savas, N., Dagli, U., Akbulut, S., Yuksel, O., Sahin, B., Colorectal cancer localization in young patients: should we expand the screening program?. Dig Dis Sci 52 (2007), 798–802.
174. Perea, J., Approach to early-onset colorectal cancer: clinicopathological, familial, molecular and immunohistochemical characteristics. World J Gastroenterol, 16, 2010, 3697.
175. da Fonseca, L.M., da Luz, M.M.P., Lacerda-Filho, A., Mônica Maria Demas, da Silva, R.G., Colorectal carcinoma in different age groups. Int J Colorectal Dis 27 (2011), 249–255.
176. Deen, K.I., Silva, H., Deen, R., Chandrasinghe, P.C., Colorectal cancer in the young, many questions, few answers. World J Gastrointest Oncol, 8, 2016, 481.
177. Rex, D.K., Johnson, D.A., Anderson, J.C., Schoenfeld, P.S., Burke, C.A., Inadomi, J.M., American college of gastroenterology guidelines for colorectal cancer screening 2008. Am J Gastroenterol 104 (2009), 739–750.
178. Mandel, J.S., Screening for colorectal cancer. Gastroenterol Clin North Am 37 (2008), 97–115.
179. Robbins, A.S., Siegel, R.L., Jemal, A., Racial disparities in stage-specific colorectal cancer mortality ratesfrom 1985 to 2008. J Clin Oncol 30 (2012), 401–405.
180. Soneji, S., Iyer, S.S., Armstrong, K., Asch, D.A., Racial disparities in stage-specific colorectal cancer mortality: 1960–2005. Am J Public Health 100 (2010), 1912–1916.
181. Phatak, U.R., Kao, L.S., Millas, S.G., Wiatrek, R.L., Ko, T.C., Wray, C.J., Interaction between age and race alters predicted survival in colorectal cancer. Ann Surg Oncol 20 (2013), 3363–3369.
182. Schellerer, V.S., Merkel, S., Schumann, S.C., Schlabrakowski, A., Förtsch, T., Schildberg, C., et al. Despite aggressive histopathology survival is not impaired in young patients with colorectal cancer. Int J Colorectal Dis 27 (2011), 71–79.
183. D'Onofrio, G.M.D., Tan, E.G.C., Is colorectal carcinoma in the young a more deadly disease?. ANZ J Surg 55 (1985), 537–540.
184. Palmer, M.L., Herrera, L., Petrelli, N.J., Colorectal adenocarcinoma in patients less than 40 years of age. Dis Colon Rectum 34 (1991), 343–346.
185. Marble, K., Banerjee, S., Greenwald, L., Colorectal carcinoma in young patients. J Surg Oncol 51 (1992), 179–182.
186. Beckman, E.N., Gathright, J.B., Ray, J.E., A potentially brighter prognosis for colon carcinoma in the third and fourth decades. Cancer 54 (1984), 1478–1481.
187. MacGillivray, D.C., Swartz, S.E., Robinson, A.M., Cruess, D.F., Smith, L.E., Adenocarcinoma of the colon and rectum in patients less than 40 years of age. Surg Gynecol Obstet 172 (1991), 1–7.
188. LaQuaglia, M.P., Heller, G., Filippa, D.A., Karasakalides, A., Vlamis, V., Wollner, N., et al. Prognostic factors and outcome in patients 21 years and under with colorectal carcinoma. J Pediatr Surg 27 (1992), 1085–1090.
189. O'Connell, J.B., Maggard, M.A., Liu, J.H., Etzioni, D.A., Livingston, E.H., Ko, C.Y., Do young colon cancer patients have worse outcomes?. World J Surg 28 (2004), 558–562.
190. Chung, Y.F., Eu, K.W., Machin, D., Ho, J.M., Nyam, D.C., Leong, A.F., et al. Young age is not a poor prognostic marker in colorectal cancer. Br J Surg 85 (1998), 1255–1259.
191. Parramore, J.B., Wei, J.P., Yeh, K.A., Colorectal cancer in patients under forty: presentation and outcome. Am Surg 64 (1998), 563–567 discussion 567–8.
192. Park, H.-C., Shin, A., Kim, B.-W., Jung, K.-W., Won, Y.-J., Oh, J.H., et al. Data on the characteristics and the survival of korean patients with colorectal cancer from the Korea central cancer registry. Ann Coloproctol 29 (2013), 144–149.
193. Ruiz, R., Taxa, L., Casanova, L., Ruiz, E., Montenegro, P., P-243 * clinicopathologic features and survival outcomes of colorectal cancer in young patients: experience from a cancer institute in Peru. Ann Oncol., 26, 2015 iv70–1.
194. Aparicio, T., Pamoukdjian, F., Quero, L., Manfredi, S., Wind, P., Paillaud, E., Colorectal cancer care in elderly patients: unsolved issues. Dig Liver Dis 48 (2016), 1112–1118.
195. Chagpar, R., Xing, Y., Chiang, Y.-J., Feig, B.W., Chang, G.J., You, Y.N., et al. Adherence to stage-specific treatment guidelines for patients with colon cancer. J Clin Oncol 30 (2012), 972–979.
196. Liang, J.-T., Huang, K.-C., Cheng, Y.-M., Hsu, H.-C., Cheng, A.-L., Hsu, C.-H., et al. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int J Cancer 97 (2002), 451–457.
197. Wallace, K., Hill, E.G., Lewin, D.N., Williamson, G., Oppenheimer, S., Ford, M.E., et al. Racial disparities in advanced-stage colorectal cancer survival. Cancer Causes Control 24 (2013), 463–471.
198. Wallace, K., DeToma, A., Lewin, D.N., Sun, S., Rockey, D., Britten, C.D., et al. Racial differences in stage IV colorectal cancer survival in younger and older patients. Clin Colorectal Cancer 16 (2017), 178–186.
199. Jessup, J.M., Milburn Jessup, J., Stewart, A., Greene, F.L., Minsky, B.D., Adjuvant chemotherapy for stage III colon cancer. JAMA, 294, 2005, 2703.
200. Yothers, G., Sargent, D.J., Wolmark, N., Goldberg, R.M., O'Connell, M.J., Benedetti, J.K., et al. Outcomes among black patients with stage II and III colon cancer receiving chemotherapy: an analysis of ACCENT adjuvant trials. J Natl Cancer Inst 103 (2011), 1498–1506.
201. Merok, M.A., Ahlquist, T., Røyrvik, E.C., Tufteland, K.F., Hektoen, M., Sjo, O.H., et al. Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series. Ann Oncol 24 (2012), 1274–1282.
202. Popat, S., Hubner, R., Houlston, R.S., Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23 (2005), 609–618.
203. Tezcan, G., Tunca, B., Ak, S., Cecener, G., Egeli, U., Molecular approach to genetic and epigenetic pathogenesis of early-onset colorectal cancer. World J Gastrointest Oncol 8 (2016), 83–98.
204. Roth, A.D., Tejpar, S., Delorenzi, M., Yan, P., Fiocca, R., Klingbiel, D., et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28 (2010), 466–474.
205. Samowitz, W.S., Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65 (2005), 6063–6069.
206. Popovici, V., Budinska, E., Tejpar, S., Weinrich, S., Estrella, H., Hodgson, G., et al. Identification of a poor-prognosis BRAF-mutant–like population of patients with colon cancer. J Clin Oncol 30 (2012), 1288–1295.
207. Ogino, S., Nosho, K., Kirkner, G.J., Kawasaki, T., Chan, A.T., Schernhammer, E.S., et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 100 (2008), 1734–1738.
208. Wolff, E.M., Byun, H.-M., Han, H.F., Sharma, S., Nichols, P.W., Siegmund, K.D., et al. Hypomethylation of a LINE-1 promoter activates an alternate transcript of the MET oncogene in bladders with cancer. PLoS Genet, 6, 2010, e1000917.
209. Jones, P.A., Baylin, S.B., The epigenomics of cancer. Cell 128 (2007), 683–692.
210. Karpf, A.R., Matsui, S.-I., Genetic disruption of cytosine DNA methyltransferase enzymes induces chromosomal instability in human cancer cells. Cancer Res 65 (2005), 8635–8639.
211. Shahrzad, S., Bertrand, K., Minhas, K., Coomber, B.L., Induction of DNA hypomethylation by tumor hypoxia. Epigenetics 2 (2007), 119–125.
212. Esteller, M., Epigenetics in cancer. N Engl J Med 358 (2008), 1148–1159.
213. Nosho, K., Baba, Y., Tanaka, N., Shima, K., Hayashi, M., Meyerhardt, J.A., et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 222 (2010), 350–366.
214. Martino-Echarri, E., Henderson, B.R., Brocardo, M.G., Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy. Oncotarget 5 (2014), 9889–9900.
215. Violette, S., Poulain, L., Dussaulx, E., Pepin, D., Faussat, A.-M., Chambaz, J., et al. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer 98 (2002), 498–504.
216. Bishnupuri, K.S., Luo, Q., Murmu, N., Houchen, C.W., Anant, S., Dieckgraefe, B.K., Reg IV activates the epidermal growth factor receptor/Akt/AP-1 signaling pathway in colon adenocarcinomas. Gastroenterology 130 (2006), 137–149.
217. Deng, J., Lei, W., Fu, J.-C., Zhang, L., Li, J.-H., Xiong, J.-P., Targeting miR-21 enhances the sensitivity of human colon cancer HT-29 cells to chemoradiotherapy in vitro. Biochem Biophys Res Commun 443 (2014), 789–795.
218. Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351 (2004), 337–345.
219. Allegra, C.J., Jessup, J.M., Somerfield, M.R., Hamilton, S.R., Hammond, E.H., Hayes, D.F., et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27 (2009), 2091–2096.
220. Knickelbein, K., Zhang, L., Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes Dis 2 (2015), 4–12.
221. Therkildsen, C., Bergmann, T.K., Henrichsen-Schnack, T., Ladelund, S., Nilbert, M., The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol 53 (2014), 852–864.
222. French, A.J., Sargent, D.J., Burgart, L.J., Foster, N.R., Kabat, B.F., Goldberg, R., et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 14 (2008), 3408–3415.
223. Alberts, S.R., Sargent, D.J., Nair, S., Mahoney, M.R., Mooney, M., Thibodeau, S.N., et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307 (2012), 1383–1393.
224. Taieb, J., Le Malicot, K., Balogoum, R., Tabernero, J., Mini, E., Folprecht, G., et al. Adjuvant FOLFOX cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: results from the PETACC8 trial. Ann Oncol, 27, 2016, 10.1093/annonc/mdw370.10.
225. Hess, G.P., Wang, P.F., Quach, D., Barber, B., Zhao, Z., Systemic therapy for metastatic colorectal cancer: patterns of chemotherapy and biologic therapy use in US medical oncology practice. J Oncol Pract 6 (2010), 301–307.
226. Allegra, C.J., Yothers, G., O'Connell, M.J., Sharif, S., Petrelli, N.J., Colangelo, L.H., et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 29 (2011), 11–16.
227. de Gramont, A., Van Cutsem, E., Schmoll, H.-J., Tabernero, J., Clarke, S., Moore, M.J., et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 13 (2012), 1225–1233.
228. Economides, A.N., Carpenter, L.R., Rudge, J.S., Wong, V., Koehler-Stec, E.M., Hartnett, C., et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 9 (2002), 47–52.
229. Davis, S.L., Eckhardt, S.G., Messersmith, W.A., Jimeno, A., The development of regorafenib and its current and potential future role in cancer therapy. Drugs Today 49 (2013), 105–115.
230. Kopetz, S., Desai, J., Chan, E., Hecht, J.R., O'Dwyer, P.J., Lee, R.J., et al. PLX4032 in metastatic colorectal cancer patients with mutant BRAF tumors. J Clin Oncol, 28, 2010, 3534.
231. Kefford, R., Arkenau, H., Brown, M.P., Millward, M., Infante, J.R., Long, G.V., et al. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol, 28, 2010, 8503.
232. Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372 (2015), 2509–2520.
233. Timmermann, B., Kerick, M., Roehr, C., Fischer, A., Isau, M., Boerno, S.T., et al. Somatic mutation profiles of MSI and MSS colorectal cancer identified by whole exome next generation sequencing and bioinformatics analysis. PLoS One, 5, 2010, e15661.
234. Eshleman, J.R., Lang, E.Z., Bowerfind, G.K., Parsons, R., Vogelstein, B., Willson, J.K., et al. Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer. Oncogene 10 (1995), 33–37.
235. Järvinen, H.J., Turunen, M.J., Colorectal carcinoma before 40 years of age: prognosis and predisposing conditions. Scand J Gastroenterol 19 (1984), 634–638.
236. McCoy, G.F., Parks, T.G., Colorectal carcinoma in young patients. A 20-year retrospective review. J R Coll Surg Edinb 29 (1984), 129–133.
237. Zauber, A.G., Lansdorp-Vogelaar, I., Knudsen, A.B., Wilschut, J., van Ballegooijen, M., Kuntz, K.M., Evaluating test strategies for colorectal cancer screening: a decision analysis for the U. S. Preventive Services Task Force. Ann Intern Med 149 (2008), 659–669.
238. Bleyer, A., CAUTION! Consider cancer: common symptoms and signs for early detection of cancer in young adults. Semin Oncol 36 (2009), 207–212.
239. Pitluk, H., Poticha, S.M., Carcinoma of the colon and rectum in patients less than 40 years of age. Surg Gynecol Obstet 157 (1983), 335–337.
240. Kim, N.H., Park, J.H., Park, D.I., Sohn, C.I., Choi, K., Jung, Y.S., The fecal immunochemical test has high accuracy for detecting advanced colorectal neoplasia before age 50. Dig Liver Dis 49 (2017), 557–561.
241. Fu, J.-F., Huang, Y.-Q., Yang, J., Yi, C.-H., Chen, H.-L., Zheng, S., Clinical characteristics and prognosis of young patients with colorectal cancer in Eastern China. World J Gastroenterol 19 (2013), 8078–8084.